查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球免疫库定序市场 - 产业分析、规模、份额、成长、趋势、预测 (2031) - 按组件、按应用、按最终用户、按地区
市场调查报告书
商品编码
1389767

全球免疫库定序市场 - 产业分析、规模、份额、成长、趋势、预测 (2031) - 按组件、按应用、按最终用户、按地区

Immune Repertoire Sequencing Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America & Middle East & Africa)
出版日期: | 出版商: Fairfield Market Research | 英文 219 Pages | 商品交期: 2-5个工作天内

价格
简介目录

次世代定序 (NGS) 技术的最新进展为免疫组库定序领域的突破性发现铺平了道路。 这项尖端技术可侦测 B 细胞受体 (BCR) 和 T 细胞受体 (TCR) 的互补决定区域，正在彻底改变我们对人体抵御外来病原体的防御机制的理解。

免疫组库定序可最大限度地减少侵入性和样品需求，提供准确且灵敏的平台，并提供感兴趣区域的动态视图。 未来，该领域新方法的发展将发挥核心作用，特别是如果它们能够提供比现有方法更全面的样本见解。 免疫组库定序的未来预计将由单细胞方法主导，该方法提供有关较小目标群体（包括抗原结合细胞）的高维度详细资讯。

根据最近的预测，全球免疫组库定序市场预计将以 7.3% 的复合年增长率成长，到 2026 年底将达到 1.73 亿美元。 从价值来看，北美已成为主导的区域市场，预计亚太地区将出现强劲成长。

在北美，由于对抗癌症和传染病的免疫疗法的需求不断增长，美国预计将引领市场。 正如美国国家癌症研究所所强调的那样，免疫组库定序方法的发展预计将在抗癌进展中发挥关键作用。

在医疗保健支出和政府资金不断增长的推动下，欧洲是免疫库测序的第二大区域市场。 该地区的竞争格局非常激烈，许多製造商为市场成长做出了贡献。 此外，基因组定序价格的下降也刺激了对免疫组库定序的需求。

亚太地区，尤其是中国和日本，全球免疫组库定序市场正经历显着成长。 在国际合作和该地区技术进步的支持下，这项技术的采用正在增加。 拉丁美洲正在经历先进产品引进和传染病发病率上升推动的成长。

本报告考察了全球免疫谱库定序市场，并提供了市场概述，包括按成分、应用、最终用户、地区划分的趋势以及进入市场的公司的竞争趋势。我是。

目录

第 1 章执行摘要

第二章市场概述

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影响分析
  • 乌克兰和俄罗斯之间衝突的影响
  • 经济概况
  • 杵分析

第 3 章 2018-2031 年全球免疫库定序市场展望

  • 2018-2031 年全球免疫组库定序市场前景（按组成部分、价值（百万美元））
  • 2018-2031 年全球免疫组库定序市场前景（按应用、价值（百万美元））
  • 2018-2031 年全球免疫组库定序市场前景（按最终用户划分）价值（百万美元）
  • 2018-2031 年全球免疫谱定序市场前景（按地区、价值（百万美元））

第 4 章 2018-2031 年北美免疫库定序市场展望

第五章欧洲免疫谱定序市场展望，2018-2031

第 6 章 2018-2031 年亚太地区免疫库定序市场展望

第 7 章拉丁美洲免疫库定序市场展望，2018-2031

第 8 章中东与非洲免疫库定序市场展望，2018-2031

第九章竞争态势

  • 以最终使用者和使用情况划分的热图
  • 按製造商和应用程式划分的热图
  • 2023 年公司市占率分析
  • 竞争力仪表板
  • 公司简介
    • Illumina, Inc.
    • Pacific Biosciences of California, Inc
    • Agilent Technologies, Inc
    • Oxford Nanopore Technologies, Ltd
    • QIAGEN N.V.
    • Thermo Fisher Scientific
    • BGI
    • Takara Bio, Inc
    • F. Hoffmann-La Roche Ltd

第 10 章附录

简介目录

Recent advancements in next-generation sequencing (NGS) technology have paved the way for groundbreaking discoveries in the field of immune repertoire sequencing. This cutting-edge technique, which probes the complementarity-determining regions of B-cell receptors (BCRs) and T-cell receptors (TCRs), is revolutionizing our understanding of the body's defense mechanisms against foreign agents.

Immune Repertoire Sequencing Unveils a World of Opportunities

Immune repertoire sequencing offers an accurate and sensitive platform with minimal invasiveness and sample requirement, providing a dynamic view of the region of interest. Looking ahead, the development of new methods in this field is poised to take center stage, particularly if they can offer more comprehensive sample insights compared to current techniques. The future of immune repertoire sequencing is expected to be dominated by single-cell approaches, offering high-dimensional and in-depth information on smaller populations of interest, including antigen-binding cells.

Market Projections and Regional Dominance

According to recent projections, the global immune repertoire sequencing market is set to grow at an impressive CAGR of 7.3% and is anticipated to reach a valuation of US$ 173.0 million by the end of 2026. In terms of value, North America is poised to emerge as the dominant regional market, with strong growth anticipated in Asia Pacific.

In North America, the United States is expected to lead the way due to a growing demand for immunotherapy in the fight against cancer and infectious diseases. Developments in immune repertoire sequencing methods are expected to play a pivotal role in the progress against cancer, as highlighted by the U.S. National Cancer Institute.

Europe is the second dominant regional market for immune repertoire sequencing, driven by increased healthcare expenditure and government funding. This region boasts a highly competitive landscape, with numerous manufacturers contributing to the market's growth. Additionally, price reductions in genome sequencing have spurred the demand for immune repertoire sequencing.

Asia-Pacific, specifically China and Japan, is witnessing significant growth in the global immune repertoire sequencing market. The adoption of this technology is on the rise, supported by international collaborations and technological advancements in the region. Latin America is experiencing growth fueled by advanced product introductions and the rising incidence of infectious diseases.

Conversely, the Middle East & Africa is expected to be the least attractive market due to challenges such as a lack of skilled personnel and limited internet access for data analysis. However, price reductions and international collaborations may spur future growth in this region.

Unlocking the Potential of Immune Repertoire Sequencing

High-throughput sequencing of immunoglobulin and TCR sequences is opening up numerous opportunities for advancing our knowledge of human biology and medicine. Immune repertoire sequencing holds immense promise in biomarker discovery, vaccine development, and transplant selectivity. However, it also comes with its share of challenges, including the need for new sequenced databases, computational algorithms, and advanced software for comprehensive data analysis.

In conclusion, the ever-evolving field of immune repertoire sequencing is poised for continuous growth, driven by scientific breakthroughs in TCR and BCR repertoire research. These developments will serve as the foundation for new clinical applications in personalized medicine, providing deeper insights into the behavior and response of adaptive immunity.

Table of Contents

1. Executive Summary

  • 1.1. Global Immune Repertoire Sequencing Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 3.1. Global Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Assay Kits
        • 3.1.1.1.1. TCR Kits
        • 3.1.1.1.2. BCR Kits
      • 3.1.1.2. Software & Services
        • 3.1.1.2.1. Analytical Software
        • 3.1.1.2.2. Sequencing Services
        • 3.1.1.2.3. Data Analysis Services
  • 3.2. Global Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Biomarker Discovery
      • 3.2.1.2. Infectious Diseases
      • 3.2.1.3. Vaccine Development and efficacy
      • 3.2.1.4. Cancer Immunotherapy
      • 3.2.1.5. Autoimmune Disease
      • 3.2.1.6. Transplant Rejection and Tolerance
      • 3.2.1.7. Others
  • 3.3. Global Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Academic Institutes
      • 3.3.1.2. Research Centres
  • 3.4. Global Immune Repertoire Sequencing Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 4.1. North America Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Assay Kits
        • 4.1.1.1.1. TCR Kits
        • 4.1.1.1.2. BCR Kits
      • 4.1.1.2. Software & Services
        • 4.1.1.2.1. Analytical Software
        • 4.1.1.2.2. Sequencing Services
        • 4.1.1.2.3. Data Analysis Services
  • 4.2. North America Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Biomarker Discovery
      • 4.2.1.2. Infectious Diseases
      • 4.2.1.3. Vaccine Development and efficacy
      • 4.2.1.4. Cancer Immunotherapy
      • 4.2.1.5. Autoimmune Disease
      • 4.2.1.6. Transplant Rejection and Tolerance
      • 4.2.1.7. Others
  • 4.3. North America Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Academic Institutes
      • 4.3.1.2. Research Centres
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 4.4.1.2. U.S. Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 4.4.1.3. U.S. Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 4.4.1.4. Canada Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 4.4.1.5. Canada Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 4.4.1.6. Canada Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 5.1. Europe Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Assay Kits
        • 5.1.1.1.1. TCR Kits
        • 5.1.1.1.2. BCR Kits
      • 5.1.1.2. Software & Services
        • 5.1.1.2.1. Analytical Software
        • 5.1.1.2.2. Sequencing Services
        • 5.1.1.2.3. Data Analysis Services
  • 5.2. Europe Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Biomarker Discovery
      • 5.2.1.2. Infectious Diseases
      • 5.2.1.3. Vaccine Development and efficacy
      • 5.2.1.4. Cancer Immunotherapy
      • 5.2.1.5. Autoimmune Disease
      • 5.2.1.6. Transplant Rejection and Tolerance
      • 5.2.1.7. Others
  • 5.3. Europe Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Academic Institutes
      • 5.3.1.2. Research Centres
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.2. Germany Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.3. Germany Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.4. U.K. Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.5. U.K. Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.6. U.K. Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.7. France Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.8. France Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.9. France Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.10. Italy Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.11. Italy Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.12. Italy Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.13. Turkey Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.14. Turkey Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.15. Turkey Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.16. Russia Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.17. Russia Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.18. Russia Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Assay Kits
        • 6.1.1.1.1. TCR Kits
        • 6.1.1.1.2. BCR Kits
      • 6.1.1.2. Software & Services
        • 6.1.1.2.1. Analytical Software
        • 6.1.1.2.2. Sequencing Services
        • 6.1.1.2.3. Data Analysis Services
  • 6.2. Asia Pacific Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Biomarker Discovery
      • 6.2.1.2. Infectious Diseases
      • 6.2.1.3. Vaccine Development and efficacy
      • 6.2.1.4. Cancer Immunotherapy
      • 6.2.1.5. Autoimmune Disease
      • 6.2.1.6. Transplant Rejection and Tolerance
      • 6.2.1.7. Others
  • 6.3. Asia Pacific Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Academic Institutes
      • 6.3.1.2. Research Centres
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.2. China Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.3. China Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.4. Japan Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.5. Japan Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.6. Japan Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.7. South Korea Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.8. South Korea Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.9. South Korea Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.10. India Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.11. India Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.12. India Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 7.1. Latin America Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Assay Kits
        • 7.1.1.1.1. TCR Kits
        • 7.1.1.1.2. BCR Kits
      • 7.1.1.2. Software & Services
        • 7.1.1.2.1. Analytical Software
        • 7.1.1.2.2. Sequencing Services
        • 7.1.1.2.3. Data Analysis Services
  • 7.2. Latin America Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
      • 7.2.1.1. Biomarker Discovery
      • 7.2.1.2. Infectious Diseases
      • 7.2.1.3. Vaccine Development and efficacy
      • 7.2.1.4. Cancer Immunotherapy
      • 7.2.1.5. Autoimmune Disease
      • 7.2.1.6. Transplant Rejection and Tolerance
      • 7.2.1.7. Others
  • 7.3. Latin America Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Academic Institutes
      • 7.3.1.2. Research Centres
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 7.4.1.2. Brazil Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 7.4.1.3. Brazil Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.4.1.4. Mexico Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 7.4.1.5. Mexico Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 7.4.1.6. Mexico Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.4.1.7. Argentina Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 7.4.1.8. Argentina Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 7.4.1.9. Argentina Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Assay Kits
        • 8.1.1.1.1. TCR Kits
        • 8.1.1.1.2. BCR Kits
      • 8.1.1.2. Software & Services
        • 8.1.1.2.1. Analytical Software
        • 8.1.1.2.2. Sequencing Services
        • 8.1.1.2.3. Data Analysis Services
  • 8.2. Middle East & Africa Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Biomarker Discovery
      • 8.2.1.2. Infectious Diseases
      • 8.2.1.3. Vaccine Development and efficacy
      • 8.2.1.4. Cancer Immunotherapy
      • 8.2.1.5. Autoimmune Disease
      • 8.2.1.6. Transplant Rejection and Tolerance
      • 8.2.1.7. Others
  • 8.3. Middle East & Africa Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Academic Institutes
      • 8.3.1.2. Research Centres
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 8.4.1.2. GCC Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.3. GCC Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.4. South Africa Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 8.4.1.5. South Africa Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.6. South Africa Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.7. Egypt Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 8.4.1.8. Egypt Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.9. Egypt Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.10. Nigeria Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 8.4.1.11. Nigeria Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.12. Nigeria Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By End User vs by Application Heat map
  • 9.2. Manufacturer vs by Application Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Illumina, Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Pacific Biosciences of California, Inc
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Agilent Technologies, Inc
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Oxford Nanopore Technologies, Ltd
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. QIAGEN N.V.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Thermo Fisher Scientific
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. BGI
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Takara Bio, Inc
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. F. Hoffmann-La Roche Ltd
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations